Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506805 · ClinicalTrials.gov registry record · Phase 1
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
A Phase 1 study of Cancer, sponsored by Esanex.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 2
- Study locations
NCT00506805: Completed Phase 1 study of Cancer, sponsored by Esanex.
NCT00506805 is a Phase 1 study of Cancer that has completed, run by Esanex. The registered enrollment target is 44 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00506805, a Phase 1 study of Cancer, has completed, sponsored by Esanex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Conditions Studied
Interventions
- DRUG SNX-5422
Study Locations (2)
Arizona
- Pfizer Investigational Site - Scottsdale
Tennessee
- Pfizer Investigational Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
What the finished NCT00506805 record still lists
NCT00506805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which SNX-5422 is the first listed.
NCT00506805 reports a single indexed study location in Arizona, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00506805 about?
NCT00506805 is a clinical study titled "Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies". Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
What is the current status of trial NCT00506805?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2007-06. Estimated completion is 2010-03.
What conditions does trial NCT00506805 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00506805?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT00506805?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00506805 being conducted?
This trial has 2 study locations across Arizona, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00506805's enrollment target sits among peer trials
44 449th of 615 higher than 162 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia